Skip to main content

Table 6 MCII and participant responders based on changes between baseline and 8 weeks and between baseline and 6 months

From: A randomised controlled trial of a self-management education program for osteoarthritis of the knee delivered by health care professionals

    Number with MCII (%)
Variables Pearson's χ2 Pvalues OAK Control
Preintervention to 8 weeks     
   WOMAC Physical Function, absolute 10.84(1, 141) P = 0.001 25 (37%) 9 (13%)
   WOMAC Physical Function (%) 19.34(1, 141) P ≤ 0.001 29 (43%) 7 (10%)
   SF-36 Physical Function 8.34(1, 140) P = 0.006 40 (60%) 23 (34%)
   SF-36 Pain 1.38(1, 139) P = 0.265 23 (34%) 17 (25%)
   VAS Pain, absolute 15.95(1, 139) P ≤ 0.001 27 (40%) 7 (10%)
   VAS Pain (%) 17.37(1, 139) P ≤ 0.001 25 (37%) 5 (7%)
   TUG 28.87(1, 139) P ≤ 0.001 46 (69%) 15 (22%)
   Responders 13.59(1, 141) P ≤ 0.001 26 (39%)b 8 (12%)b
Preintervention to 6 months     
   WOMAC Physical Function, absolute 3.87(1, 135) P = 0.057 24 (14%) 14 (20%)
   WOMAC Physical Function (%) 4.37(1, 135) P = 0.043 27 (40%) 15 (22%)
   SF-36 Physical Function 2.93(1, 136) P = 0.122 40 (60%) 29 (43%)
   SF-36 Pain 0.95(1, 135) P = 0.384 31 (46%) 25 (37%)
   TUG 5.10(1, 132) P = 0.036 38 (57%) 26 (38%)
   Responders 2.58(1, 135) P = 0.123 22 (33%)b 14 (20%)b
  1. aMCII: minimal clinically important improvement; OARSI: Osteoarthritis Research International; OMERACT: Outcome Measures in Rheumatology; SF-36: Short Form 36 version 1 questionnaire; TUG: Timed Up & Go Test; VAS: Visual Analogue Scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index. bData are number of responders based on the OMERACT-OARSI criteria [46].